Tianyan Pharmaceutical will announce the preclinical data of two transformative antibody projects at the ASH annual meeting

Suzhou, China and San Diego, USA November 5, 2021/PRNewswire/ - Tianyan Pharmaceutical (hereinafter referred to as the "Company" or "Tianyan") (NASDAQ: ADAG) is a platform-driven clinic A stage biopharmaceutical company dedicated to discovering and developing new cancer immunotherapies based on original antibodies

Pre-clinical data showed that ADG153 (an anti-CD47 safety antibody SAFEbodyTM) and ADG152 (combining the company's proprietary bispecific CD3 T cell adaptor platform and safety antibody SAFEbodyTM masking technology to generate a powerful CD20xCD3 antibody POWERbody™) are significant Differentiated characteristics

The specific information displayed on the poster during the 2021ASH Annual Conference is as follows:

Abstract Title: ADG153, a new anti-CD47 monoclonal safety antibody to target related reference clinical antibodies: stronger in vivo anti-tumor activity, longer half-life, minimal red blood cell toxicity and CD47 antigen silencing

Abstract Number: 3342

Date: Eastern Time, Monday, December 13, 2021

Poster Exhibition III: 9:00 am-8:00 pm EDT

Venue and time (on-site participants): Hall B5, 6:00pm-8:00pm EST Abstract Title: ADG152, the new CD20xCD3 bispecific safety antibody exhibits strong anti-tumor activity and higher safety

Abstract Number: 1204

Date: Eastern Time, Saturday, December 11, 2021

Poster Exhibition I: 9:00 am-7:30 pm EDT

Venue and time (on-site participants): Hall B5, 5:30 pm-7:30 pm Eastern Time

"We are very pleased to disclose the preclinical data of ADG152 and ADG153 for the first time.

Dr.

These preclinical research results also demonstrate the advantages of Tianyan's artificial intelligence-driven antibody discovery and development platform based on the design and construction of antibody dynamic characteristics

At present, Tianyan continues to expand and promote innovative preclinical product pipelines, including ADG152 and ADG153, and five projects are in the preclinical research (IND-enabling) stage of new drug applications

About Tianyan Pharmaceutical

Tianyan Pharmaceutical (NASDAQ: ADAG) is a platform-driven biopharmaceutical company in the clinical product development stage with independent platform output.

For more information, please visit: https://investor.

Safe Harbor Statement

This press release contains forward-looking statements, including statements about ADG152 and ADG153 preclinical studies, the potential impact of ADG152 and ADG153 preclinical research results, as well as the advancement of Tianyan Pharmaceuticals and expected clinical development, regulatory milestones, and Tianyan Pharmaceuticals Commercialization of pipeline candidate products

Source: Tianyan Pharmaceutical